Replimune, Inc.

Nasdaq REPL · Woburn, MA

Works in Dermatology · GI & liver · Infectious disease · Oncology · Ophthalmology · Respiratory

Replimune, Inc. is a clinical trial sponsor based in Woburn, MA, listed as Nasdaq REPL. It has 9 active clinical trials with 1,589 planned participants, across 6 therapeutic areas. Since 2021 it has completed 0 trials and stopped 2 early.

Trial track record · since 2021

9Active trials1,589 planned participants
0Completed0 with results posted
2Stopped earlyterminated, withdrawn or suspended

Financials · Nasdaq REPL

Cash and equivalents
R&D expense
Net income (loss)
Cash runway

Pipeline · 9 active trials

StageTrialStatus

Questions about Replimune, Inc

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-07-15.

Approve Suite is not affiliated with Replimune, Inc..

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.